Samantha Herretes, MD
Cornea and External Diseases Specialist · Kansas City, MONPI 1770995862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,566 of the $11,145 with a category attached, or 76.9%. 20 manufacturers reported payments, led by Alcon at 44.5% of the total. Reporting peaked in 2024 at $4,277 and has fallen 72.7% since, to $1,168 in 2025.
Across 162 payments — averaging $68.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- Biotissue Holdings Inc.$3K
- Sight Sciences, Inc.$748
- Bausch & Lomb Americas Inc.$591
- Sun Pharmaceutical Industries Inc.$390
- Novartis$349
- plus $1K from 14 others
What the payments were for
- Travel & lodging$2,48222%
- Food & beverage$8,56677%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 73 | $4,962 |
| Biotissue Holdings Inc. | 16 | $2,769 |
| Sight Sciences, Inc. | 12 | $748 |
| Bausch & Lomb Americas Inc. | 13 | $591 |
| Sun Pharmaceutical Industries Inc. | 9 | $390 |
| Novartis | 5 | $349 |
| Mallinckrodt Hospital Products Inc. | 8 | $249 |
| Astellas Pharma Global Development | 2 | $155 |
| Rxsight Inc | 2 | $146 |
| Oyster Point Pharma, Inc. | 6 | $144 |
| AbbVie | 2 | $141 |
| Dompe US, Inc. | 1 | $118 |
| Glaukos Corporation | 1 | $108 |
| Tarsus Pharmaceuticals, Inc. | 3 | $77 |
| Leadiant Biosciences, Inc. | 2 | $49 |
| Harrow Eye, LLC | 2 | $49 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$922
- AcrySof$517
- AcrySof IQ PanOptix$344
- CEQUA$240
- ARGOS$239
- XIIDRA$235
- Clareon PanOptix Pro$143
- OMNI(R) SURGICAL SYSTEM (US)$139
- SION SURGICAL INSTRUMENT$139
- enVista MX60 IOL$137
- AcrySof IQ VIVITY IOL$135
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$132
- LenSx$128
- RESTASIS$125
- AmnioGraft$123
- Precision 1$123
- Oxervate$118
- IC-8 Apthera IOL$118
- MIEBO$115
- Izervay$112
How this compares
Too few cornea and external diseases specialist providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 217 | $162,585 |
| Cyclosporine | 117 | $46,943 |
| XiidraLifitegrast | 44 | $42,355 |
| Prednisolone Acetate | 619 | $25,409 |
| TyrvayaVarenicline Tartrate | 21 | $14,021 |
| Fluorometholone | 147 | $12,622 |
| CequaCyclosporine | 17 | $10,747 |
| Ofloxacin | 251 | $3,154 |
| FlarexFluorometholone Acetate | 14 | $3,120 |
| ValacyclovirValacyclovir Hcl | 73 | $2,423 |
| Loteprednol Etabonate | 12 | $2,237 |
| ErythromycinErythromycin Base | 134 | $1,764 |
| MoxifloxacinMoxifloxacin Hcl | 36 | $1,397 |
| Doxycycline Hyclate | 35 | $749 |
| Ketorolac Tromethamine | 32 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $141 | $162,585217 claims |
| Bausch & Lomb Americas Inc.Xiidra | $591 | $42,35544 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $144 | $14,02121 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $390 | $10,74717 claims |
| Eyevance Pharmaceuticals LLCFlarex | $19 | $3,12014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Missourion file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Kansas City
- Yong KamKansas City$2K
- Jing-Wei HuangSaint Louis$58K
- Frederick FraunfelderColumbia$12K
- Todd MargolisSaint Louis$9K
- Laurence DuckerColumbia$6K
- James LandreneauColumbia$2K
- Jennifer EnrightSaint Louis$2K
- Augustine HongSaint Louis$1K
- Marilyn CollinsSaint Louis$861
- Deena ShaathSaint Louis$345
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.